Seres Therapeutics Inc (MCRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.72+1.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MCRB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | |
|---|---|---|---|
| Revenues | |||
| Revenues | 1.9 | 0.8 | — |
| Total Revenues | 1.9 | 0.8 | — |
| Operating Expenses & Income | |||
| R&D Expenses | 46.6 | 49.1 | 64.6 |
| Operating Income | (84.0) | (94.0) | (121.3) |
| Earnings from Continuing Operations | |||
| Interest & Investment Income | 1.6 | 2.2 | 4.0 |
| Other Non-Operating Income / Expenses | 61.6 | 99.7 | (4.5) |
| Net Income | |||
| Net Income | (22.5) | 5.7 | 0.1 |
| Per Share | |||
| Basic EPS | (2.31) | 0.64 | 0.00 |
| Diluted EPS | (2.30) | 0.64 | 0.00 |
| Revenue per Share | 0.19 | — | — |
| Basic Weighted Avg Shares | 9.7 | 8.9 | 155.4 |
| Diluted Weighted Avg Shares | 9.7 | 8.9 | 155.4 |
| Supplemental | |||
| EBITDA | — | (89.8) | (115.8) |
| EBIT | (84.0) | (94.0) | (121.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.